Operating Income: The income after operating expenses.
Denali Therapeutics Inc. (DNLI) had Operating Income of $-137.37M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-128.55M |
|
-- |
|
-- |
|
$137.37M |
|
|
Operating Income |
$-137.37M |
$8.92M |
|
$-128.45M |
|
$-128.45M |
|
$-128.55M |
|
$-128.55M |
|
$-128.55M |
|
$-128.55M |
|
$-137.37M |
|
$-136.14M |
|
172.65M |
|
172.65M |
|
$-0.73 |
|
$-0.73 |
|
| Balance Sheet Financials | |
$900.66M |
|
$52.40M |
|
$244.20M |
|
$1.14B |
|
$98.35M |
|
$5.53M |
|
$32.74M |
|
$131.09M |
|
$1.01B |
|
$1.01B |
|
$1.01B |
|
156.18M |
|
| Cash Flow Statement Financials | |
$-412.60M |
|
$255.28M |
|
$189.22M |
|
$176.53M |
|
$208.43M |
|
$31.90M |
|
$99.63M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.16 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-422.10M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.68% |
|
-12.68% |
|
-11.23% |
|
-12.61% |
|
$6.49 |
|
$-2.44 |
|
$-2.39 |
|